<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999983</url>
  </required_header>
  <id_info>
    <org_study_id>29760</org_study_id>
    <nct_id>NCT03999983</nct_id>
  </id_info>
  <brief_title>Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)</brief_title>
  <acronym>VOTER</acronym>
  <official_title>Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective registry of patients admitted for stroke and evidence of Vertebral Artery
      Origin Stenosis (VAOS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective registry of stenting plus medical management for the prevention of recurrent
      stroke in patients with symptomatic Vertebral Artery origin Stenosis (VAOS). Looking at
      clinical outcomes at 30 days and 1-year post-treatment and angiographic outcomes at 1-year
      post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Incidence of recurrent stroke or death</measure>
    <time_frame>1 Year post-treatment</time_frame>
    <description>Recurrent stroke of any type or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Restenosis</measure>
    <time_frame>1 Year post-treatment</time_frame>
    <description>Restenosis in VAOS patients treated with drug-eluting stents.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vertebral Artery Stenosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational Prospective Registry</intervention_name>
    <description>This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment</description>
    <other_name>Observational</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients between 18 and 90 years of age

          2. Patient has experienced a posterior circulation ischemic event

          3. Patient has angiographically confirmed bilateral vertebral artery origin disease
             (Hypoplasia, occlusion, or stenosis).

          4. Patient has &gt;50% stenosis on the side being targeted for therapy

        Exclusion Criteria:

          1. Pregnant women

          2. Contrast Indication to the use of anti-platelet drugs

          3. There is tandem vertebral or basilar artery stenosis

          4. The serum creatinin is &gt;2.5

          5. Baseline modified Rankin score is &gt;3

          6. &lt; 5 years life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Randall Edgell, MD</last_name>
    <phone>314-577-6161</phone>
    <email>randall.edgell@health.slu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Guthrie, BS</last_name>
    <phone>314-577-6165</phone>
    <email>andre.guthrie@health.slu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Guthrie, BS, CCRP</last_name>
      <phone>314-577-6165</phone>
      <email>andre.guthrie@health.slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kara Christopher, MS, MPH, PhD</last_name>
      <phone>314-577-6167</phone>
      <email>kara.christopher@health.slu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randall Edgell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Randall C. Edgell, MD, FSVIN</investigator_full_name>
    <investigator_title>Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertebrobasilar Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

